TABLE 1.
Patient characteristics and univariate analysis of the risk of lymph node metastasis.
| Variable | Primary cohort (n = 234) |
Validation cohort (n = 191) |
||||
| Node negative | Node positive | P | Node negative | Node positive | P | |
| (n = 173) | (n = 61) | (n = 131) | (n = 60) | |||
| Age (year), n (%) | 0.346 | 0.008 | ||||
| <50 | 83 (48.0) | 25 (41.0) | 64 (48.9) | 17 (28.3) | ||
| ≥50 | 90 (52.0) | 36 (59.0) | 67 (51.1) | 43 (71.7) | ||
| Menopause, n (%) | 0.257 | 0.027 | ||||
| No | 94 (54.3) | 28 (45.9) | 75 (57.3) | 24 (40.0) | ||
| Yes | 79 (45.7) | 33 (54.1) | 56 (42.7) | 36 (60.0) | ||
| Number of pregnancies, n (%) | 0.442 | 0.635 | ||||
| <3 | 75 (43.4) | 23 (37.7) | 52 (39.7) | 26 (43.3) | ||
| ≥3 | 98 (56.6) | 38 (62.3) | 79 (60.3) | 34 (56.7) | ||
| Hypertension, n (%) | 0.185 | 0.500 | ||||
| No | 151 (87.3) | 49 (80.3) | 112 (85.5) | 49 (81.7) | ||
| Yes | 22 (12.7) | 12 (19.7) | 19 (14.5) | 11 (18.3) | ||
| Diabetes, n (%) | >1.000 | >1.000 | ||||
| No | 167 (96.5) | 59 (96.7) | 122 (93.1) | 56 (93.3) | ||
| Yes | 6 (3.5) | 2 (3.3) | 9 (6.9) | 4 (6.7) | ||
| Tumor histology, n (%) | 0.099 | 0.337 | ||||
| Squamous cell cancer | 138 (79.8) | 54 (88.6) | 108 (82.4) | 52 (86.7) | ||
| Adenocarcinoma | 22 (12.7) | 6 (9.8) | 13 (10.0) | 2 (3.3) | ||
| Adenosequamous cancer | 9 (5.2) | 0 (0.0) | 7 (5.3) | 5 (8.3) | ||
| Others | 4 (2.3) | 1 (1.6) | 3 (2.3) | 1 (1.7) | ||
| 2018 FIGO stage, n (%) | <0.001 | <0.001 | ||||
| IA | 9 (5.2) | 0 (0.0) | 9 (6.9) | 0 (0.0) | ||
| IB | 136 (78.6) | 27 (44.3) | 77 (58.8) | 26 (43.3) | ||
| IIA | 28 (16.2) | 34 (55.7) | 45 (34.3) | 34 (56.7) | ||
| SCCA (ng/mL) | ||||||
| Mean (SD) | 1.9 (2.4) | 8.8 (13.1) | <0.001 | 2.8 (3.4) | 12.5 (15.3) | <0.001 |
| Tumor size in PET/CT (cm) | ||||||
| Mean (SD) | 2.2 (1.7) | 4.1 (1.9) | <0.001 | 2.7 (1.5) | 4.3 (1.7) | <0.001 |
| LN diameter in PET/CT (cm) | ||||||
| Mean (SD) | 0.4 (0.4) | 1.0 (0.7) | <0.001 | 0.3 (0.4) | 1.2 (1.1) | <0.001 |
| tSUVmax | ||||||
| Mean (SD) | 8.3 (6.1) | 11.2 (6.3) | <0.001 | 8.6 (6.3) | 11.7 (5.1) | <0.001 |
| nSUVmax | ||||||
| Mean (SD) | 0.7 (1.1) | 4.5 (4.5) | <0.001 | 0.6 (1.1) | 4.6 (5.4) | <0.001 |
| nSUVmax/tSUVmax | ||||||
| Mean (SD) | 0.1 (0.2) | 0.5 (0.5) | <0.001 | 0.1 (0.2) | 0.4 (0.6) | <0.001 |
| Uterine corpus invasion in PET/CT, n (%) | <0.001 | <0.001 | ||||
| No | 163 (94.2) | 34 (55.7) | 114 (87.0) | 27 (45.0) | ||
| Yes | 10 (5.8) | 27 (44.3) | 17 (13.0) | 33 (55.0) | ||
| LN status in PET/CT, n (%) | <0.001 | <0.001 | ||||
| No | 132 (76.3) | 12 (19.7) | 105 (80.2) | 18 (30.0) | ||
| Yes | 41 (23.7) | 49 (80.3) | 26 (19.8) | 42 (70.0) | ||
LN, lymph node; SCCA, squamous cell carcinoma associated antigen; SUVmax, maximum standardized uptake value; nSUVmax, SUVmax of lymph node; tSUVmax, SUVmax of tumor; PET/CT, positron emission tomography/computed tomography.